Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ drug therapy
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Dietary Supplements
Disease Models, Animal
Docetaxel
/ pharmacology
Docosahexaenoic Acids
/ pharmacology
Drug Synergism
Female
Humans
Mice
Signal Transduction
/ drug effects
Triple Negative Breast Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
Apoptosis
Cell cycle
Fatty acids
Ki67
Tumor growth
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
04
2019
accepted:
18
06
2019
pubmed:
27
6
2019
medline:
10
1
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
The objective of this study was to investigate if DHA dietary supplementation enhances the anticancer actions of docetaxel (TXT) in two different drug resistant triple negative breast cancer (TNBC) patient-derived xenografts (PDX)s. In two experiments, female NSG mice bearing TNBC PDXs were randomized to one of two nutritionally adequate diets (20% w/w): control (0% DHA), or DHA (3.9% w/w of total fat) and injected with 0 or 5 mg/kg TXT, twice weekly for 6 weeks (n = 8 per group). Treatment response was determined by significant differences in tumor weight, and apoptotic, proliferation and cell cycle markers at endpoint. Mice bearing MAXF574 xenografts fed DHA diet and treated with TXT had a 57% reduction in tumor weight compared to mice fed control diet (P < 0.004), a 64% reduction compared to control + TXT (P < 0.01) and a 34% reduction compared to DHA with no TXT (P < 0.04). DHA + TXT reduced MAXF401 xenografts growth compared to control and control + TXT (by 43% and 34%, respectively, P < 0.05). In both xenografts, DHA + TXT resulted in a higher expression of proapoptotic proteins Ripk1 and Bid, lower expression of proliferation marker Ki67 and anti-apoptotic proteins Bcl-2 and Parp, and a greater increase in cell cycle arrest as measured by decreased Survivin expression when compared to control + TXT mice (P < 0.05). This work is the first to confirm that DHA supplementation during chemotherapy treatment improves TXT action in two PDX models of TNBC. The results suggest that decreases in tumor size occurred via changes in apoptosis, cell proliferation, and cell cycle pathways.
Identifiants
pubmed: 31236812
doi: 10.1007/s10549-019-05331-8
pii: 10.1007/s10549-019-05331-8
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
357-367Subventions
Organisme : Canadian Institutes of Health Research
ID : RES0037745
Pays : Canada
Références
World Health Organization (2017) Cancer: World Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/
Turashvili G, Brogi E (2017) Tumor heterogeneity in breast cancer. Front Med 4:227
doi: 10.3389/fmed.2017.00227
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M et al (2016) Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35(4):547–573
doi: 10.1007/s10555-016-9653-x
pubmed: 28025748
pmcid: 5396460
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
doi: 10.1016/S0092-8674(00)81683-9
Hanahan D, Weinberg Robert A (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627–636
doi: 10.1007/s10549-010-1293-1
pubmed: 21161370
Hurvitz S, Mead M (2016) Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol 28(1):59–69
pubmed: 26694831
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657
doi: 10.1200/JCO.2006.06.5664
pubmed: 17116942
Ho MY, Mackey JR (2014) Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 6:253–259
doi: 10.2147/CMAR.S40601
pubmed: 24904223
pmcid: 4041377
Noguchi S (2006) Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 97:813–820
doi: 10.1111/j.1349-7006.2006.00265.x
pubmed: 16805818
Eliseo D, Velotti F (2016) Omega-3 fatty acids and cancer cell cytotoxicity: implications for multi-targeted cancer therapy. J Clin Med 5(2):15
doi: 10.3390/jcm5020015
pmcid: 4773771
Newell M, Baker K, Postovit LM, Field CJ (2017) A critical review on the effect of docosahexaenoic acid (DHA) on cancer cell cycle progression. Int J Mol Sci 18(8):1784
doi: 10.3390/ijms18081784
pmcid: 5578173
Liu J, Ma DW (2014) The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer. Nutrients 6(11):5184–5223
doi: 10.3390/nu6115184
pubmed: 25412153
pmcid: 4245586
Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N et al (2005) Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 55(1):12–20
doi: 10.1007/s00280-004-0846-6
pubmed: 15365767
Ewaschuk JB, Newell M, Field CJ (2012) Docosahexanoic acid improves chemotherapy efficacy by inducing CD95 translocation to lipid rafts in ER(−) breast cancer cells. Lipids 47(11):1019–1030
doi: 10.1007/s11745-012-3717-7
pubmed: 23054549
Granci V, Cai F, Lecumberri E, Clerc A, Dupertuis YM, Pichard C (2013) Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. Br J Nutr 109(7):1188–1195
doi: 10.1017/S000711451200308X
pubmed: 22874769
Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI (2006) Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 118(10):2584–2593
doi: 10.1002/ijc.21555
pubmed: 16353135
Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD (2008) Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68(15):1635–1646
doi: 10.1002/pros.20830
pubmed: 18668525
Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, Maheo K (2008) Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44(7):1483–1491
doi: 10.1016/j.freeradbiomed.2008.01.009
pubmed: 18267129
Chauvin L, Goupille C, Blanc C, Pinault M, Domingo I, Guimaraes C et al (2016) Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCepsilon/delta-induced ERK pathways. Biochim Biophys Acta 1861(4):380–390
doi: 10.1016/j.bbalip.2016.01.012
pubmed: 26821209
Newell M, Brun M, Field CJ (2019) Treatment with DHA modifies the response of MDA-MB-231 breast cancer cells and tumors from nu/nu mice to doxorubicin through apoptosis and cell cycle arrest. J Nutr 149:46–56
doi: 10.1093/jn/nxy224
pubmed: 30601995
Whittle JR, Lewis MT, Lindeman GJ, Visvader JE (2015) Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 17(1):17
doi: 10.1186/s13058-015-0523-1
pubmed: 25849559
pmcid: 4323263
Ellis LM, Fidler IJ (2010) Finding the tumor copycat: therapy fails, patients don’t. Nat Med 16:974
doi: 10.1038/nm0910-974
pubmed: 20823880
Gillet J-P, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI et al (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108(46):18708–18713
doi: 10.1073/pnas.1111840108
pubmed: 22068913
Hait WN (2010) Anticancer drug development: the grand challenges. Nat Rev Drug Discovery 9:253
doi: 10.1038/nrd3144
pubmed: 20369394
Gould SE, Junttila MR, de Sauvage FJ (2015) Translational value of mouse models in oncology drug development. Nat Med 21(5):431–439
doi: 10.1038/nm.3853
pubmed: 25951530
Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G (2014) Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res 16:R36
doi: 10.1186/bcr3640
pubmed: 24708766
pmcid: 4053092
Robinson LE, Field CJ (1998) Dietary long-chain (n-3) fatty acids facilitate immune cell activation in sedentary, but not exercise-trained rats. J Nutr 128(3):498–504
doi: 10.1093/jn/128.3.498
pubmed: 9482755
Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le FO (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101(12):1978–1985
doi: 10.1038/sj.bjc.6605441
pubmed: 19920822
pmcid: 2779856
DeRuiter FE, Dwyer J (2002) Consumer acceptance of irradiated foods: dawn of a new era? Food Serv Technol 2(2):47–58
doi: 10.1046/j.1471-5740.2002.00031.x
VanderSluis L, Mazurak VC, Damaraju S, Field CJ (2017) Determination of the relative efficacy of eicosapentaenoic acid and docosahexaenoic acid for anti-cancer effects in human breast cancer models. Int J Mol Sci 18(12):2607
doi: 10.3390/ijms18122607
pmcid: 5751210
Schley PD, Jijon HB, Robinson LE, Field CJ (2005) Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 92(2):187–195
doi: 10.1007/s10549-005-2415-z
pubmed: 15986129
Subedi K, Yu HM, Newell M, Weselake RJ, Meesapyodsuk D, Qiu X et al (2015) Stearidonic acid-enriched flax oil reduces the growth of human breast cancer in vitro and in vivo. Breast Cancer Res Treat 149(1):17–29
doi: 10.1007/s10549-014-3212-3
pubmed: 25417173
Darwito D, Dharmana E, Riwanto I, Budijitno S, Suwardjo S, Purnomo J et al (2019) Effects of Omega-3 supplementation on Ki-67 and VEGF expression levels and clinical outcomes of locally advanced breast cancer patients treated with neoadjuvant CAF chemotherapy: a Randomized Controlled Trial Report. Asian Pac J Cancer Prevention 20(3):911–916
doi: 10.31557/APJCP.2019.20.3.911
Germain E, Chajes V, Cognault S, Lhuillery C, Bougnoux P (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75(4):578–583
doi: 10.1002/(SICI)1097-0215(19980209)75:4<578::AID-IJC14>3.0.CO;2-5
pubmed: 9466659
Maheo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, Bougnoux P et al (2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med. 39(6):742–751
doi: 10.1016/j.freeradbiomed.2005.04.023
pubmed: 16109304
Mason JK, Klaire S, Kharotia S, Wiggins AKA, Thompson LU (2015) α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways. Lipids Health Dis 14:91
doi: 10.1186/s12944-015-0090-6
pubmed: 26282560
pmcid: 4539855
deGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba J-M et al (2003) Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 14:1051–1056
doi: 10.1093/annonc/mdg291
pubmed: 12853346
Xue M, Wang Q, Zhao J, Dong L, Ge Y, Hou L et al (2014) Docosahexaenoic acid inhibited the Wnt/β-Catenin pathway and suppressed breast cancer cells in vitro and in vivo. J Nutr Biochem 25(2):104–110
doi: 10.1016/j.jnutbio.2013.09.008
pubmed: 24290517
Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, Choudhury GG et al (2009) Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 118(1):213–228
doi: 10.1007/s10549-008-0227-7
pubmed: 18953692
Kang KS, Wang P, Yamabe N, Fukui M, Jay T, Zhu BT (2010) Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS ONE 5(4):e10296
doi: 10.1371/journal.pone.0010296
pubmed: 20421971
pmcid: 2858652
Rose DP, Connolly JM (1997) Dietary fat and breast cancer metastasis by human tumor xenografts. Breast Cancer Res Treat 46(2–3):225–237
doi: 10.1023/A:1005971317978
pubmed: 9478277
Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117(8):1775–1782
doi: 10.1002/cncr.25709
pubmed: 21360698
Mocellin MC, Silva A, Camargo Q, Fabre ME, Gevaerd S, Naliwaiko K et al (2013) Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids 48(9):879–888
doi: 10.1007/s11745-013-3816-0
pubmed: 23888317
Bonatto SJ, Oliveira HH, Nunes EA, Pequito D, Iagher F, Coelho I et al (2012) Fish oil supplementation improves neutrophil function during cancer chemotherapy. Lipids 47(4):383–389
doi: 10.1007/s11745-011-3643-0
pubmed: 22160495
Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V (2003) Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 3(4):291–306
doi: 10.2174/1568011033482422
pubmed: 12769774
Schley PD, Brindley DN, Field CJ (2007) (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 137(3):548–553
doi: 10.1093/jn/137.3.548
pubmed: 17311938
Mansara PP, Deshpande RA, Vaidya MM, Kaul-Ghanekar R (2015) Differential ratios of omega fatty acids (AA/EPA + DHA) modulate growth, lipid peroxidation and expression of tumor regulatory MARBPs in breast cancer cell lines MCF7 and MDA-MB-231. PLoS ONE 10(9):e0136542
doi: 10.1371/journal.pone.0136542
pubmed: 26325577
pmcid: 4556657
Grammatikos SI, Subbaiah PV, Victor TA, Miller WM (1994) n-3 and n-6 fatty acid processing and growth effects in neoplastic and non-cancerous human mammary epithelial cell lines. Br J Cancer 70:219–227
doi: 10.1038/bjc.1994.283
pubmed: 8054269
pmcid: 2033515
Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M et al (2015) Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells. In Vitro Cell Dev Biol Anim 51(2):121–127
doi: 10.1007/s11626-014-9822-6
pubmed: 25413005
McIlwain DR, Berger T, Mak TW (2013) Caspase functions in cell death and disease. Cold Spring Harbor Persp Biol 5(4):a008656
Duriez PJ, Shah GM (1997) Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 75(4):337–349
doi: 10.1139/o97-043
pubmed: 9493956
Yang D, Chen M-B, Wang L-Q, Yang L, Liu C-Y, Lu P-H (2013) Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis. J Exp Clin Cancer Res 32(1):105
doi: 10.1186/1756-9966-32-105
pubmed: 24370277
pmcid: 3922829
Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220
doi: 10.1200/JCO.2005.07.501
pubmed: 16192605
Dowsett M, Nielsen TO, Hern R, Bartlett J, Coombes RC, Cuzick J et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI 103(22):1656–1664
doi: 10.1093/jnci/djr393
pubmed: 21960707
Matsubara N, Mukai H, Fujii S, Wada N (2013) Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat 137(1):203–212
doi: 10.1007/s10549-012-2344-6
pubmed: 23184081
McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta (BBA) 1785(2):96–132
Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK (2003) Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2(6):549–555
pubmed: 12813134
Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338–345
doi: 10.1038/nature12625
pubmed: 24048066
Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000–5005
doi: 10.1158/1078-0432.CCR-08-0746
pubmed: 18698017
Hinnis AR, Luckett JCA, Walker RA (2007) Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96(4):639–645
doi: 10.1038/sj.bjc.6603616
pubmed: 17285125
pmcid: 2360044
Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851(4):469–484
doi: 10.1016/j.bbalip.2014.08.010
pubmed: 25149823
Robinson LE, Clandinin MT, Field CJ (2002) The role of dietary long-chain n-3 fatty acids in anti-cancer immune defense and R3230AC mammary tumor growth in rats: influence of diet fat composition. Breast Cancer Res Treat 73(2):145–160
doi: 10.1023/A:1015261111605
pubmed: 12088117
Paixao E, Oliveira ACM, Pizato N, Muniz-Junqueira MI, Magalhaes KG, Nakano EY et al (2017) The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naive breast cancer patients: a randomized double-blind controlled trial. Nutr J 16(1):71
doi: 10.1186/s12937-017-0295-9
pubmed: 29061183
pmcid: 5653994
Yu HM, Newell M, Subedi K, Weselake RJ, Mazurak V, Field CJ (2015) Bypassing the Δ6-desaturase enzyme and directly providing n-3 and n-6 PUFA pathway intermediates reduces the survival of two human breast cancer cell lines. Eur J Lipid Sci Technol 117(9):1378–1390
doi: 10.1002/ejlt.201400464